Company Information

  

Address: XTL BIOPHARMACEUTICALS LTD
C/O ALSTON & BIRD LLP, 90 PARK AVENUE 
City: NEW YORK 
State: NY 
Zip Code: 10016 
Telephone: 972 9 955 7080 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a biopharmaceutical company engaged in the development of therapeutics for the treatment of neuropathic pain and hepatitis C. We are developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain. We are also developing several novel pre-clinical hepatitis C small molecule inhibitors. We also have an active in-licensing and acquisition program designed to identify and acquire additional drug candidates.

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
12/20170.00NAN/E
12/2016-0.05NAN/E
12/2015-0.25NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.06Total Liab/Total Assets0.45
Net Inc/Total Assets-0.12Total Liab/Inv Cap0.47
Net Inc/Inv Cap-0.12Total Liab/Comm Equity0.23
Pretax Inc/Net SalesNAInterest Coverage Ratio-96.62
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio20.69
Inventory TurnoverNACurrent Ratio20.69
Inventory Day SalesNANet Rec/Curr Assets0.02
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  12/31/2017 12/31/2016 12/31/2015 12/31/2014
Total Revenues(Net Sales) NA NA NA NA
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 1.20 1.27 1.43 1.74
Operating Income -1.25 -2.56 -3.61 -2.02
Interest Exp 0.01 0.01 0.02 0.11
Pretax Income -0.78 -2.55 -3.62 -2.12
Other Income 0.47 0.02 0.00 0.01
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -0.78 -2.55 -4.31 -2.87

Balance Sheet (Millions)

Assets 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Cash & Short Term Investments 3.59 2.43 4.07 2.16
Receivables - Total 0.11 0.32 0.20 0.44
Inventories - Total NA NA NA NA
Total Current Assets 6.21 2.75 4.27 3.10
Net Property, Plant & Equipment 0.00 0.01 0.01 0.02
Total Assets 6.59 3.02 5.32 5.64
Liabilities        
Accounts Payable 0.30 0.33 0.44 0.52
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 0.30 0.33 0.44 0.97
Long-Term Debt NA NA NA NA
Total Liabilities 2.97 0.33 0.44 0.98
Stockholder's Equity        
Minority Interest NA NA NA 0.02
Preferred Stock NA NA NA NA
Common Stock 13.18 6.62 6.61 6.20
Retained Earnings -155.65 -154.90 -152.49 -148.32
Treasury Stock NA NA NA -1.50
Total Stockholders' Equity 3.62 2.69 4.89 4.66
Total Liabilities and Stockholders' Equity 6.59 3.02 5.32 5.64

Cash Flow Summary (Millions)

Categories 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Cash Provided by Operating Activities -1.13 -1.73 -1.86 -2.47
Net Cash Provided by Investing Activities -2.50 -0.07 -0.11 1.50
Net Cash Provided by Financing Activities 4.89 0.00 3.58 0.31

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.00-3.71--
12/20140.00-2.86--
12/20150.00-4.31-0.25
12/20160.00-2.54-0.05
12/20170.00-0.780.00
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional03/31/184370.73




Report Date : 4/16/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.